CTNM
Contineum Therapeutics Inc. - Ordinary Shares - Class A

143
Mkt Cap
$569.13M
Volume
117,658.00
52W High
$16.01
52W Low
$3.35
PE Ratio
-6.91
CTNM Fundamentals
Price
$15.58
Prev Close
$16.00
Open
$15.84
50D MA
$12.75
Beta
0.44
Avg. Volume
272,336.50
EPS (Annual)
-$1.63
P/B
2.52
Rev/Employee
$0.00
$180.27
Loading...
Loading...
News
all
press releases
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·4d ago
News Placeholder
More News
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Rating Increased to Hold at Wall Street Zen
Wall Street Zen raised shares of Contineum Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...
MarketBeat·8d ago
News Placeholder
Is Contineum Therapeutics, Inc. (CTNM) Stock Outpacing Its Medical Peers This Year?
Here is how Contineum Therapeutics, Inc. (CTNM) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.
Zacks·18d ago
News Placeholder
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Moderate Buy" from Analysts
Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the seven analysts that are currently covering the firm, MarketBeat reports...
MarketBeat·22d ago
News Placeholder
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation...
Business Wire·25d ago
News Placeholder
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Contineum Therapeutics, Inc. (NASDAQ:CTNM - Get Free Report) have been given an average recommendation of "Moderate Buy" by the eight research firms that are currently covering the company...
MarketBeat·2mo ago
News Placeholder
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock?
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks·2mo ago
News Placeholder
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 91.5% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·2mo ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded shares of Contineum Therapeutics from a "sell" rating to a "hold" rating in a research report on Sunday...
MarketBeat·2mo ago
News Placeholder
Contineum Therapeutics (NASDAQ:CTNM) Stock Rating Lowered by Wall Street Zen
Wall Street Zen lowered shares of Contineum Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...
MarketBeat·2mo ago
<
1
2
...
>

Latest CTNM News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.